If you have been reading about lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-08. Numbers and descriptions here follow the published literature rather than marketing material.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
=== Pollution and phytoremediation === EcM fungi have been found to have beneficial effects in several types of polluted environments, including: • High salt: A number of studies have shown that certain EcM fungi can help their hosts survive high soil salinity conditions. • Radionuclides: Many species of ectomycorrhizal fungi, including the Cortinariaceae, can hyperaccumulate radionuclides • Organic pollutants: Some EcM species are capable of decomposing persistent organic pollutants (POPs) such as organochlorides and polychlorinated biphenyls (PCBs). Chemicals that can be detoxified by EcM fungi, either alone or in association with their host plant, include 2,4-dichlorophenol and tetrachloroethylene.
Half-Life 2: Episode Three is a canceled first-person shooter game developed by Valve. It was planned as the last in a trilogy of episodic games continuing the story of Half-Life 2 (2004). Valve announced Episode Three in May 2006, with a release planned for 2007. Following the cliffhanger ending of Episode Two (2007), it was widely anticipated. Episode Three was to be set in the Arctic and introduce elements such as an ice gun and a blob-like enemy. Marc Laidlaw, the writer for the Half-Life series, intended it to end the Half-Life 2 story arc. Little information was released over the following years, and in 2011 Wired described it as vaporware. Valve eventually canceled Episode Three as they had become fatigued with Half-Life and could not settle on a direction. Additionally, they wanted to create more ambitious games and felt limited by the episodic format. They delayed development of a new Half-Life game until their new game engine, Source 2, was complete. Laidlaw left Valve in 2016. In 2017, he released a short story that journalists speculated was a summary of the Episode Three plot. In response, fans launched projects attempting to recreate Episode Three. After canceling several further Half-Life games, Valve released a virtual reality game, Half-Life: Alyx, in 2020.
Work has also been done for long-chain fatty acids and found that even-numbered sites, which are thought to be derived from C2 position of the acetyl group, are more enriched in 2H than odd-numbered hydrogen that come from C1 position of the acetyl group. Duan et al. reported a strong KIE during the desaturation from oleic acid to linoleic acid. In summary, the underlying physics of SNIF-NMR enables it to measure isotopomers. Another advantage of NMR measurement over mass spectrometry is that it analyzes samples non-destructively. 2H SNIF-NMR has been well industrialized in source identification and forensics, and has contributed much to biochemical pathway studies. The application of 2H SNIF-NMR to geological records is sporadic and still needs exploring.
Sources: en.wikipedia.org
Involuntarily, I compare the mummified sovereign—now small and weathered—to the giant man I saw in 1886 entering the See of São Paulo. Amidst a colossal wave of people, he dominated the crowd, appearing many cubits taller. The body of Pedro II and that of his wife Teresa Cristina (who was also embalmed) were officially repatriated to Brazil aboard a Brazilian Navy ship in 1921. The emperor and empress are now interred in the Imperial Mausoleum within the Cathedral of Saint Peter of Alcantara in Petrópolis, a city founded by Pedro II himself.
During the Islamic Golden Age under the Abbasid Caliphate, prominent Muslim physicians preserved, systematized and developed ancient medical knowledge from across the Eurasian continent. They synthesized concepts from classical antiquity (see: Ancient Greece, Ancient Rome), Persia, Ayurveda, and China. This work laid the foundations for later advances in medieval European medicine as European physicians came into contact with Islamic authors through the Renaissance of the 12th century. Rhazes (c. 865–925), or Muhammad ibn Zakariya al-Razi, included writings about diabetes in the more than 230 books he produced in his lifetime. Avicenna (980–1037), or Ibn Sina, was a court physician to the caliphs of Baghdad and a key figure in medicine who compiled an exhaustive medical encyclopedia titled The Canon of Medicine. His account detailed the clinical features of diabetes, and termed the disease albulab ("water wheel") and zalkh el kuliah ("diarrhea of the kidneys"). He documented "the abnormal appetite and the collapse of sexual functions" and the sweet taste of diabetic urine, and further differentiated diabetes associated with emaciation from other causes of polyuria. He also elaborated on diabetic gangrene and treated diabetes using a mixture of lupine, trigonella (fenugreek), and zedoary seed. It has been noted that references to diabetes expanded in the medical texts of this period. Eknoyan and Nagy (2005) speculate that this indicates the increasing prevalence of the disease.
It has also been reported as a folk remedy for diabetes: since inulin is not assimilated in the intestine, it does not cause a glycemic spike as potatoes would. Temperature variances have been shown to affect the amount of inulin the Jerusalem artichoke can produce. It makes less inulin in a colder region than when it is in a warmer region.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.